RxDoctor Payments Data

Ling Yi Obrand, MD

Internal Medicine · Las Vegas, NVNPI 1295225399

Payments from drug & device makers

$263in general payments, 2019–2025

Across 16 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$66
  • Boehringer Ingelheim$57
  • Biohaven Pharmaceutical Holding Company Ltd.$53
  • Alkermes, Inc.$29
  • Pfizer$18
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$17
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$263100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$263 in reported general payments places this provider in the 50th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$16,632
Medicare patients
97
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$93,639
EliquisApixaban26$35,431
TrulicityDulaglutide18$25,706
OzempicSemaglutide14$23,685
ProliaDenosumab13$23,126
JanuviaSitagliptin Phosphate18$22,902
RybelsusSemaglutide13$22,411
XareltoRivaroxaban17$21,671
TradjentaLinagliptin19$18,943
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,615
Breo ElliptaFluticasone/Vilanterol27$11,249
PremarinEstrogens, Conjugated15$6,497
Spiriva RespimatTiotropium Bromide11$5,887
Atorvastatin Calcium576$5,058
Gabapentin165$3,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$57$118,469106 claims
Novo NordiskOzempic, Rybelsus$66$46,09727 claims
PfizerEliquis, Premarin$18$41,92841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →